El interés en corto de Butterfly Network da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Butterfly Network. Los datos de interés en corto se actualizan cada dos semanas.

Butterfly Network (NYSE:BFLY) Bolsa, Informe de interés en corto

Butterfly Network

Butterfly Network Inc is a digital health business transforming care with handheld, whole-body ultrasound. Powered by its proprietary Ultrasound-on-Chip technology, its solution enables the acquisition of imaging information from an affordable, powerful device that fits in a healthcare professional's pocket with a combination of cloud-connected software and hardware technology that is easily accessed through a mobile application. Butterfly enables the practical application of ultrasound information in the clinical workflow. Butterfly iQ+ is an ultrasound device that can perform whole-body imaging in a single handheld probe using semiconductor technology. With its small, handheld size, low cost, and simple user interface.

Long Ideas

News

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

BFLY

CTOS

NINE

Descubre las compras más importantes de insiders en penny stocks tras la reciente caída del Dow Jones. ¿Oportunidad de inversión?

Butterfly Network y otras 2 penny stocks que los insiders están comprando

Butterfly Network, Inc. Class A Common Stock

Butterfly Network Inc

<h3>Gainers</h3>
<ul>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares rose 58.1% to $0.95 during Thursday's after-market session. The company's market cap stands at $9.6 million. </li>
<li>SunLink Health Systems (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SSY#AMEX">SSY</a>) shares increased by 17.13% to $0.95. The company's market cap stands at $6.6 million. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) shares increased by 5.55% to $1.14. The company's market cap stands at $3.2 million. </li>
<li>Butterfly Network (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) shares moved upwards by 5.17% to $1.83. The market value of their outstanding shares is at $389.0 million. </li>
<li>Nurix Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) shares moved upwards by 5.16% to $22.99. The market value of their outstanding shares is at $1.4 billion. </li>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) shares moved upwards by 5.07% to $1.34. The market value of their outstanding shares is at $7.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock fell 6.5% to $0.45 during Thursday's after-market session. The market value of their outstanding shares is at $9.5 million. </li>
<li>Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) shares declined by 5.1% to $2.42. The market value of their outstanding shares is at $2.0 million. </li>
<li>Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) stock declined by 4.76% to $239.49. The market value of their outstanding shares is at $28.8 billion. </li>
<li>Processa Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) stock declined by 4.69% to $1.22. The market value of their outstanding shares is at $3.9 million. </li>
<li>Tango Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNGX#NASDAQ">TNGX</a>) shares fell 4.59% to $6.25. The market value of their outstanding shares is at $669.6 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock declined by 4.5% to $6.59. The company's market cap stands at $85.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AKAN

KDLY

KLTO

NIVF

NRIX

PCSA

PHIO

TNGX

12 Health Care Stocks Moving In Thursday's After-Market Session

<ul>
<li>URMC increased ultrasound charge capture by 116% following system-wide deployment of Butterfly Network devices and Compass&#x2122; workflow software.</li>
<li>URMC's implementation results <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicalimagingscience.org%2Froadmap-to-success-blueprint-for-enterprise-wide-deployment-of-a-point-of-care-ultrasound-platform-inclusive-of-governance-policy-education-credentialing-and-quality-assurance%2F&amp;esheet=54122956&amp;newsitemid=20240917669860&amp;lan=en-US&amp;anchor=published&amp;index=1&amp;md5=c524e8d8dd5268a5f512603c0986c7de">published</a> on September 16, 2024 in the Journal of Clinical Imaging Science.</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.butterflynetwork.com&amp;esheet=54122956&amp;newsitemid=20240917669860&amp;lan=en-US&amp;anchor=Butterfly+Network%2C+Inc.&amp;index=2&amp;md5=feb818b2cf773f1940ad96704c5916ac">Butterfly Network, Inc.</a> ("Butterfly", "the Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>), a digital health company transforming care through the power of portable, semiconductor-based ultrasound technology and intuitive software, today published a <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbutterflynetwork.com%2Fcase-studies-urmc&amp;esheet=54122956&amp;newsitemid=20240917669860&amp;lan=en-US&amp;anchor=case+study&amp;index=3&amp;md5=edcc066ce0d00e71b94c89e2a2016144">case study</a> highlighting the positive impact of University of Rochester Medical Center's (URMC) transformative, system-wide deployment of Butterfly's point-of-care ultrasound (POCUS) devices and enterprise ultrasound platform, Compass&#x2122;. The results are backed by an <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicalimagingscience.org%2Froadmap-to-success-blueprint-for-enterprise-wide-deployment-of-a-point-of-care-ultrasound-platform-inclusive-of-governance-policy-education-credentialing-and-quality-assurance%2F&amp;esheet=54122956&amp;newsitemid=20240917669860&amp;lan=en-US&amp;anchor=academic+paper&amp;index=4&amp;md5=6901dde3885271a01a52a19178f2c937">academic paper</a> published yesterday, September 16, 2024, in the Journal of Clinical Imaging Science.

Biotech

General

University Of Rochester Medical Center Boosts Diagnostic Accuracy And Workflow Efficiency With Butterfly Network's Enterprise Ultrasound Solution; URMC Increased Ultrasound Charge Capture By 116% Following System-Wide Deployment Of Butterfly Network Devices And Compass Workflow Software

WIIM

Butterfly Network shares are trading higher after Lake Street initiated coverage on the stock with a Buy rating and announced $3 price target.

Lake Street initiates coverage on Butterfly Network (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) with a Buy rating and announces Price Target of $3.

Price Target

Initiation

Analyst Ratings

Lake Street Initiates Coverage On Butterfly Network with Buy Rating, Announces Price Target of $3

Shares of Butterfly Network (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bfly#NYSE">BFLY</a>) closed 26.9% higher on Sept. 4 after the company announced the commercial launch of its third-generation handheld point-of-care ultrasound system, Butterfly iQ3, in Europe. Investors are likely upbeat about the news due to the strong uptake of Butterfly iQ3 in the U.S. market following its February launch.
Butterfly iQ3 received EU MDR certification in March and is fully compliant with the Restriction of Hazardous Substances Directive. The device will currently be available in all European countries and the United Kingdom. It was launched in Canada during the second quarter. The company is now applying for regulatory approval for iQ3 in additional regions.
The Butterfly iQ3 is the company&#39;s most advanced portable ultrasound device in its portfolio which includes the second-generation iQ+ device. The Butterfly iQ3 uses BFLY&#39;s most advanced P4.3 chip that has double the processing power compared to iQ+ for best-in-class image quality, new advanced 3D imaging tools for easier use and a smaller, more ergonomic design. Moreover, the higher selling price of the device compared to iQ+ should accelerate the revenue growth rate.
BFLY&#39;s shares have gained 39.9% so far this year, significantly outperforming the industry&#39;s decline of 13.5% on the back of the rising adoption of Butterfly iQ3 in the U.S. market. The S&amp;P 500 Index has gained 15.9% in the same period.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/d3/76630.jpg?v=1658840067" /> 
Image Source: Zacks Investment Research
<h2>US Performance of BFLY&#39;s iQ3</h2>
Butterfly Network&#39;s 16% top-line growth in the second quarter was primarily driven by robust uptake of Butterfly iQ3 in the United States and additional sales from launch in Canada.&nbsp;Of the company&#39;s total online orders, 74% were for iQ3 during the quarter. iQ3 represented 89% of sales across all channels in Canada. Moreover, the company initiated a competitive device upgrade in the second quarter, allowing customers to turn their old non-butterfly product into a new iQ3. This represents an additional growth opportunity for the company as it upgraded over a thousand probes in the second quarter.
During the second quarter, iQ3 sales represented 50% of total unit sales, with 75% of total units sold in the United States.
<h2>BFLY&#39;s iQ3 to Improve Patient Care</h2>
The company&#39;s new advanced 3D capabilities, iQ Slice and iQ Fan for Butterly iQ3 make image capturing easier. iQ Slice helps to capture up to 46 ultrasound slices at a time across a wide angle. The imaging mode is designed to make it easier and faster to acquire excellent images without skilled maneuvering. On the other hand, iQ Fan is a dedicated lung tool that reduces the movements necessary to capture information and make informed clinical decisions.
These two new features come with Butterfly&#39;s existing robust feature list of more than 20 anatomical presets, six imaging modes and a collection of artificial intelligence, advanced imaging tools and a rich set of Calculation tools.
Apart from its rich features, Butterfly iQ3&#39;s smaller and ergonomic design is fueling its strong adoption in the United States and Canada, which is likely to continue to reflect in European markets as well. The device has a 17% smaller probe face and is 7% shorter in size than iQ+. The new device also comes with a stronger battery with up to 2 hours of thermal run time for outstanding continuous scanning and charges 2.5 times faster.
These features are helping the Butterfly iQ3 device to significantly enhance the echo image quality and the biplane mode for cannulation, which has already proven beneficial in managing patients with challenging IV access.
<div class="chart_embed">
<h3>Butterfly Network, Inc. Price</h3>
<img alt="Butterfly Network, Inc. Price" src="https://staticx-tuner.zacks.com/images/charts/75/1725523014.png" style="height:254px; width:572px" title="" />
Butterfly Network, Inc. price | Butterfly Network, Inc. Quote
</div>
<h2>BFLY&#39;s Zacks Rank &amp; Other Stocks to Consider</h2>
Butterfly Network currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space are&nbsp;Boston Scientific&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>),&nbsp;Apyx Medical (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apyx#NASDAQ">APYX</a>) and&nbsp;Universal Health Services (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uhs#NYSE">UHS</a>), each carrying a Zacks Rank #2 at present.
Boston Scientific has a long-term estimated growth rate of 12.6%. BSX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.2%.
Boston Scientific&#39;s shares have risen 41.4% year to date compared with the&nbsp;industry&#39;s 12.3% growth.
Apyx Medicalhas an estimated growth rate of 20% for 2025. Its earnings missed estimates in each of the trailing four quarters, delivering a negative average surprise of 25.98%.
Apyx Medical&#39;s shares have lost 49.3% year to date against the&nbsp;industry&#39;s 12.3% growth.
Universal Health Services has a long-term estimated growth rate of 19%. UHS&#39; earnings surpassed estimates in each of the trailing four quarters, the average surprise being 14.58%.
Universal Health Services&#39; shares have risen 56.1% year to date compared with the&nbsp;industry&#39;s 48% growth.
<a href="https://www.zacks.com/stock/news/2331850/butterfly-network-s-stock-surges-on-iq3-device-launch-in-europe?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2331850">To read this article on Zacks.com click here.</a>

Earnings

Earnings Beats

Large Cap

Small Cap

Tech

APYX

Butterfly Network's Stock Surges on iQ3 Device Launch in Europe

Butterfly Network shares are trading higher after the company launched its next-generation butterfly iQ3 in Europe, offering advanced 3d imaging and enhanced portability across 16 countries.

Butterfly Network Launches Next-Generation Butterfly iQ3 In Europe, Offering Advanced 3D Imaging And Enhanced Portability Across 16 Countries Including The UK, Germany, And France​

The Dow Jones index closed higher by more than 200 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Hydrofarm Holdings Group</h3>
<ul>
<li>The Trade: Hydrofarm Holdings Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYFM#NASDAQ">HYFM</a>) Director, CEO and Chairman of the Board William Douglas Toler <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 100,000 shares</a> at an average price of $0.50. To acquire these shares, it cost around $49,800.</li>
<li>What's Happening: On Aug. 8, Hydrofarm Holdings Group reported $54.8 million in net revenue for the second quarter representing a 13.1% year-over-year decrease from $63.1 million.</li>
<li>What Hydrofarm Holdings Group Does: Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies.</li>
</ul>
<h3 class="wp-block-heading">Neuronetics</h3>
<ul>
<li>The Trade: Neuronetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) Director Glenn P Muir acquired a total of 25,000 shares at an average price of $0.85. To acquire these shares, it cost around $21,250.</li>
<li>What's Happening: On Aug. 12, Neuronetics reported worse-than-expected second-quarter financial results and issued third-quarter revenue guidance below estimates.</li>
<li>What Neuronetics Does: Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders.</li>
</ul>
<h3 class="wp-block-heading">Butterfly Network</h3>
<ul>
<li>The Trade: Butterfly Network, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) Director Larry Robbins <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 1,676,869 shares</a> at an average price of $1.00. The insider spent around $1.68 million to buy those shares.</li>
<li>What's Happening: On Aug. 28, ENDRA Life Sciences announced it was granted an extension to regain Nasdaq compliance status.</li>
<li>What Butterfly Network Does: Butterfly Network Inc is a digital health business transforming care with handheld, whole-body ultrasound.</li>
</ul>
<h3 class="wp-block-heading">Castellum</h3>
<ul>
<li>The Trade: Castellum, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTM#NYSE">CTM</a>) General Counsel, Secretary Jay O Wright acquired a total of 61,597 shares at an average price of $0.16. The insider spent around $10,102 to buy those shares.</li>
<li>What's Happening: On Aug. 9, Castellum posted second-quarter revenue of $11.5 million.</li>
<li>What Castellum Does: Castellum Inc is engaged in providing information technology services.</li>
</ul>
Read More:<a href="https://www.benzinga.com/markets/24/08/40666406/top-2-real-estate-stocks-that-could-blast-off-this-quarter"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/24/08/40666406/top-2-real-estate-stocks-that-could-blast-off-this-quarter">Top 2 Real Estate Stocks That Could Blast Off This Quarter</a></li>
</ul>

HYFM

STIM

Butterfly Network And 3 Other Stocks Under $2 Executives Are Aggressively Buying

The Dow Jones index closed lower by over 200 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Nine Energy Service</h3>
<ul>
<li>The Trade: Nine Energy Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NINE#NYSE">NINE</a>) 10% owner William Monroe <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 470,362 shares</a> at an average price of $1.58. To acquire these shares, it cost around $744,019.</li>
<li>What's Happening: On Aug. 5, Nine Energy Service posted downbeat quarterly results.</li>
<li>What Nine Energy Service Does: Nine Energy Service Inc is a North American onshore completion and production services provider</li>
</ul>
<h3 class="wp-block-heading">Custom Truck One Source</h3>
<ul>
<li>The Trade: Custom Truck One Source, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTOS#NYSE">CTOS</a>) President -Rentals Thomas R. Rich <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 26,200 shares </a>at an average price of $3.84. To acquire these shares, it cost around $100,653.</li>
<li>What's Happening: On Aug. 1, Custom Truck One Source reported worse-than-expected second-quarter financial results.</li>
<li>What Custom Truck One Source Does: Custom Truck One Source Inc is a one-stop-shop provider of specialty equipment in the electric utility transmission and distribution, forestry, telecom, waste management, rail, and infrastructure end-markets in North America.</li>
</ul>
<h3 class="wp-block-heading">Butterfly Network</h3>
<ul>
<li>The Trade: Butterfly Network, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) President and CEO Joseph Devivo <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 104,000 shares</a> at an average price of $0.95. The insider spent around $98,519 to buy those shares.</li>
<li>What's Happening: On Aug. 1, Butterfly Network reported better-than-expected second-quarter financial results.</li>
<li>What Butterfly Network Does: Butterfly Network Inc is a digital health business transforming care with handheld, whole-body ultrasound.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40218858/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields</a></li>
</ul>

Butterfly Network And 2 Other Stocks Under $5 Insiders Are Buying

Butterfly Network shares are trading higher after the company reported better-than-expected Q2 financial results.

Guidance
Affirmed Revenue Guidance and improved Adjusted EBITDA guidance for the Fiscal Year 2024 to:
<ul>
<li>Affirm revenue guidance of $75 million to $80 million or approximately 15-20% growth</li>
<li>Improved adjusted EBITDA guidance by $5 million to a loss of $50 million - $45 million</li>
</ul>

Guidance

Butterfly Network Affirms FY24 Revenue $75M-$80M Vs $76.33M Est.

Butterfly Network (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.10) by 50 percent. The company reported quarterly sales of $21.487 million which beat the analyst consensus estimate of $19.580 million by 9.74 percent. This is a 16.23 percent increase over sales of $18.487 million the same period last year.

Butterfly Network Q2 2024 Adj. EPS $(0.05) Beats $(0.10) Estimate, Sales $21.487M Beat $19.580M Estimate

<ul>
<li>With iQ+ Bladder, Butterfly expands outside its core point-of-care ultrasound market to better serve the bladder scanning market with its proprietary Ultrasound-on-Chip&#x2122; technology.</li>
<li>The bundled bladder solution includes an iQ+ Bladder probe, streamlined software, compact rolling cart, tablet and power splitter, paired with premium assembly.</li>
</ul>
Butterfly Network, Inc. ("Butterfly", "the Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>), a digital health company transforming care through the power of portable, semiconductor-based ultrasound technology and intuitive software, today introduced its first specialty product, iQ+ Bladder&#x2122;, now available for purchase in the United States. The bundled solution includes an iQ+ Bladder probe, streamlined software, compact rolling cart, tablet and power splitter, paired with premium assembly. Combined, the solution offers a fit-for-purpose ultrasound-based bladder scanner that helps nurses get automated bladder volume calculations, with 3D visualizations, in seconds.

Butterfly Network Enters Bladder Scanning Market With iQ+ Bladder

<h3>Gainers</h3>
<ul>
<li>Allarity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLR#NASDAQ">ALLR</a>) stock moved upwards by 106.6% to $2.83 during Thursday's pre-market session. The market value of their outstanding shares is at $5.5 million. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares moved upwards by 52.84% to $2.95. The market value of their outstanding shares is at $154.5 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock rose 35.41% to $1.3. The company's market cap stands at $4.6 million. </li>
<li>Context Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTX#NASDAQ">CNTX</a>) stock rose 34.55% to $1.83. The company's market cap stands at $29.2 million. </li>
<li>Skye Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>) stock increased by 25.09% to $16.0. The company's market cap stands at $449.0 million. </li>
<li>Butterfly Network (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) stock increased by 24.52% to $0.98. The market value of their outstanding shares is at $203.9 million. The company's, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) stock fell 12.5% to $0.1 during Thursday's pre-market session. The market value of their outstanding shares is at $1.2 million. </li>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) stock fell 11.7% to $4.53. The company's market cap stands at $306.8 million. </li>
<li>Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) stock decreased by 11.06% to $1.93. The market value of their outstanding shares is at $191.4 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Concord Medical Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCM#NYSE">CCM</a>) shares decreased by 10.92% to $0.68. The market value of their outstanding shares is at $29.5 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock declined by 9.95% to $0.62. The company's market cap stands at $119.8 million. </li>
<li>Pharming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAR#NASDAQ">PHAR</a>) shares decreased by 9.86% to $9.42. The company's market cap stands at $634.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLR

APVO

ARAY

CNTX

CTMX

DBVT

PHAR

SKYE

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Butterfly Network shares are trading higher after the company reported better-than-expected Q1 financial results.

Shares of Aspen Aerogels, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) rose sharply in today's pre-market trading after the company reported better-than-expected <a href="https://www.benzinga.com/quote/ASPN/earnings">first-quarter financial results</a>.
Aspen Aerogels posted a GAAP loss of 2 cents per share, compared to market expectations for a loss of 11 cents per share. The company's quarterly sales came in at $94.501 million versus estimates of $75.004 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Aspen Aerogels shares jumped 26.2% to $19.21 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) gained 72.1% to $3.32 in pre-market trading after the company announced operational changes to stabilize its financial position and reported first-quarter financial results.</li>
<li>Aptevo Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) gained 38.5% to $1.33 in pre-market trading after jumping around 35% on Wednesday.</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) rose 34.8% to $117.46 in today's pre-market trading after the company announced upbeat quarterly results.</li>
<li>Enovix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) jumped 21.4% to $7.90 in pre-market trading after the company reported mixed first-quarter financial results.</li>
<li>Ondas Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONDS#NASDAQ">ONDS</a>) shares gained 16.5% to $0.97 in pre-market trading.</li>
<li>Butterfly Network, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) shares gained 15.6% to $0.9101 in pre-market trading after the company reported better-than-expected first-quarter financial results.</li>
<li>Rent the Runway, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENT#NASDAQ">RENT</a>) shares rose 14.2% to $14.14 in pre-market trading after surging 22% on Wednesday.</li>
<li>Prime Medicine Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>) shares gained 13.8% to $6.00 in pre-market trading after gaining 7% on Wednesday.</li>
<li>Rush Street Interactive, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSI#NYSE">RSI</a>) shares rose 12.6% to $7.23 in pre-market trading after the company reported better-than-expected first-quarter financial results and issued FY24 revenue guidance above estimates.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Fastly, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) fell 31.8% to $8.82 in pre-market trading after the company reported first-quarter financial results. The company said it expects second-quarter revenue in a range of $130 million and $134 million, versus the $140.16 million analyst estimate.</li>
<li>Freshworks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) shares declined 28.6% to $13.02 in pre-market trading after the company reported first-quarter financial results and announced a CEO transition. Baird analyst Rob Oliver downgraded Freshworks from Outperform to Neutral and lowered the price target from $28 to $16.</li>
<li>CytomX Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) fell 17.4% to $4.24 in pre-market trading. CytomX Therapeutics shares jumped 215% on Wednesday after the company announced that it will report first-quarter 2024 results and provide an initial CX-904 Phase 1a dose escalation update on May 8, 2024.</li>
<li>Remitly Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELY#NASDAQ">RELY</a>) shares fell 16.7% to $14.58 in pre-market trading after the company reported mixed first-quarter financial results.</li>
<li>Etsy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) shares fell 13.2% to $60.45 in pre-market trading after the company reported worse-than-expected first-quarter financial results.</li>
<li>DoorDash, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) fell 12.5% to $111.50 pre-market trading after the company reported mixed first-quarter financial results.</li>
<li>IM Cannabis Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCC#NASDAQ">IMCC</a>) shares declined 11.2% to $0.9858 in pre-market trading after gaining around 29% on Wednesday.</li>
<li>Qorvo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) shares fell 10.6% to $100.00 in pre-market trading following weak first-quarter guidance.</li>
<li>Visionary Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GV#NASDAQ">GV</a>) shares declined 11.8% to $0.20 in pre-market trading after falling 6% on Wednesday.</li>
<li>Zillow Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>) fell 6.5% to $39.19 pre-market trading after the company reported its first-quarter financial results.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/05/38573272/investor-optimism-improves-slightly-following-fed-decision">Investor Optimism Improves Slightly Following Fed Decision</a>

ASPN

CVNA

DASH

ENVX

ETSY

FRSH

FSLY

IMCC

ONDS

PRME

QRVO

RELY

RENT

Why Aspen Aerogels Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving Premarket

<div>The company sees Adjusted EBITDA loss of&nbsp;$55 million&nbsp;-&nbsp;$50 million versus prior view of Adjusted EBITDA loss of&nbsp;$60 million&nbsp;-&nbsp;$50 million.</div>

Butterfly Network Now Sees FY24 Revenue Of $75M-$80M (Est $72.855M) Or Approximately 15-20% Revenue Growth (Prior View Low Double Digit Revenue Growth)

<h3>Gainers</h3>
<ul>
<li>Pulmonx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) shares rose 29.5% to $10.0 during Wednesday's after-market session. The market value of their outstanding shares is at $388.1 million. The company's, Q1 earnings came out today. </li>
<li>Butterfly Network (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) shares moved upwards by 18.15% to $0.93. The company's market cap stands at $193.5 million. As per the press release, Q1 earnings came out today. </li>
<li>Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) stock rose 11.46% to $1.75. The market value of their outstanding shares is at $240.7 million. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares increased by 9.2% to $0.27. The market value of their outstanding shares is at $4.2 million. </li>
<li>Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) shares moved upwards by 6.47% to $101.0. The market value of their outstanding shares is at $6.3 billion. </li>
<li>Asensus Surgical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ASXC#AMEX">ASXC</a>) stock rose 6.32% to $0.25. The market value of their outstanding shares is at $69.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Envista Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVST#NYSE">NVST</a>) stock decreased by 12.5% to $17.29 during Wednesday's after-market session. The company's market cap stands at $2.9 billion. As per the press release, Q1 earnings came out today. </li>
<li>Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) shares declined by 12.45% to $1.9. The market value of their outstanding shares is at $188.4 million. As per the news, the Q3 earnings report came out today. </li>
<li>Allakos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLK#NASDAQ">ALLK</a>) stock declined by 9.74% to $1.02. The market value of their outstanding shares is at $90.3 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares decreased by 7.5% to $1.11. The market value of their outstanding shares is at $14.8 million. </li>
<li>Schrodinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDGR#NASDAQ">SDGR</a>) stock fell 7.37% to $23.4. The market value of their outstanding shares is at $1.7 billion. The company's, Q1 earnings came out today. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) stock fell 6.94% to $1.88. The company's market cap stands at $16.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLK

ASXC

BPMC

CMPX

INDP

LUNG

NVST

SDGR

STSS

12 Health Care Stocks Moving In Wednesday's After-Market Session

Butterfly Network Q2 2024 Earnings Preview

Butterfly Network GAAP EPS of -$0.07 beats by $0.03, revenue of $21.49M beats by $1.91M

Butterfly Network, Inc. (BFLY) Q2 2024 Earnings Call Transcript

Analyst Josh Jennings from TD Cowen reiterated a Buy rating on Butterfly Network (BFLY – Research Report) and keeping the price target at $3.00. Jo...

Buy Rating Affirmed: Butterfly Network's Impressive Sales and Strong Growth Trajectory

Oppenheimer analyst Suraj Kalia maintained a Buy rating on Butterfly Network (BFLY – Research Report) today and set a price target of $3.75. The co...

Oppenheimer Keeps Their Buy Rating on Butterfly Network (BFLY)

In a report released today, Josh Jennings from TD Cowen maintained a Buy rating on Butterfly Network (BFLY – Research Report), with a price target ...

TD Cowen Sticks to Their Buy Rating for Butterfly Network (BFLY)

After bouncing back from the early August dip, the stock market opened September with another round of losses. In volatile times, investors need a ...

Insiders Pour Million-Plus Dollars Into These 2 Stocks — Here's Why You Should Take Notice

Small-cap stocks have climbed recently. Here are the ones most poised for further upside

Analyst Josh Jennings from TD Cowen maintained a Buy rating on Butterfly Network (BFLY – Research Report) and keeping the price target at $3.00. Jo...

Buy Rating Affirmed: Butterfly Network's AI Integration Sets Stage for Market Differentiation and Growth

Butterfly Network: Can't Fly Much Higher

AQST

BILL

BYRN

CDNA

CLOV

COMM

CURI

DAVE

ESOA

EVER

GTHX

HRTG

HYLN

INSG

JAGGF

OPFI

PRAX

PSIX

PSNL

SUPV

USAP

Press Releases

Butterfly Network Reports Second Quarter 2024 Financial Results

Avive Welcomes Katerina Miras as Vice President of Marketing

Butterfly Network to Participate in TD Cowen's 9th Annual FutureHealth Conference

Butterfly Network Appoints Steve Cashman as Chief Business Officer

Butterfly Network to Participate in Lake Street Capital Markets' 8th Annual Best Ideas Growth Conference "Big 8"

Fit to Work: Intelligent Bio Solutions' (NASDAQ: INBS) Vision for a Healthier, Safer Workplace WISA, BFLY, CLOV, PRSO

Fierce Names Butterfly Network as a Fierce 50 Honoree of 2024

Small Cap Up Big Following Coverage Initiation And Buy Rating

University of Rochester Medical Center Boosts Diagnostic Accuracy and Workflow Efficiency with Butterfly Network's Enterprise Ultrasound Solution

Kansas City University Sets New Standard in Point-of-Care Ultrasound Education with AI-Guided Training Curriculum

Comments

Butterfly Network

Interés en corto

Butterfly Network (NYSE:BFLY) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL